Revenue declined from $65.7M in 2025Q1 to $47.3M in 2026Q2 and operating margin stayed negative at -15.1% despite an 88.8% gross margin, indicating that SG&A growth has not been matched by top-line recovery.
LifeMD, Inc. (LFMD) annual income statement — 15-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 188.94M | 194.06M | 212.45M | 152.55M | 119.03M | 92.88M | 37.29M | 12.47M | 8.32M | 5.05M | 5.24M | 1.22M | 714.16K | 808.36K | 673.78K | 743.83K |
| Revenue Growth % | -25.13% | -8.66% | 39.27% | 28.15% | 28.16% | 149.04% | 199.1% | 49.79% | 64.68% | -3.51% | 329.79% | 70.67% | -11.65% | 19.97% | -9.42% | - |
| Cost of Goods Sold | 29.65M | 39.29M | 24.07M | 18.9M | 18.67M | 18M | 8.86M | 2.53M | 1.97M | 1.48M | 1.95M | 247.77K | 172.85K | 181.3K | 125.62K | 241.26K |
| COGS % of Revenue | - | 20.25% | 11.33% | 12.39% | 15.68% | 19.38% | 23.76% | 20.25% | 23.65% | 29.35% | 37.15% | 20.33% | 24.2% | 22.43% | 18.64% | 32.44% |
| Gross Profit | 159.28M | 154.76M | 188.39M | 133.65M | 100.37M | 74.88M | 28.43M | 9.94M | 6.36M | 3.57M | 3.29M | 971.09K | 541.31K | 627.06K | 548.16K | 502.56K |
| Gross Margin % | 84.31% | 79.75% | 88.67% | 87.61% | 84.32% | 80.62% | 76.24% | 79.75% | 76.35% | 70.65% | 62.85% | 79.67% | 75.8% | 77.57% | 81.36% | 67.56% |
| Gross Profit Growth % | - | -17.85% | 40.96% | 33.16% | 34.03% | 163.36% | 185.95% | 56.46% | 77.96% | 8.46% | 239.06% | 79.4% | -13.68% | 14.39% | 9.07% | - |
| Operating Expenses | 180.91M | 162.43M | 204.53M | 148.14M | 143.81M | 129.18M | 86.25M | 12.83M | 8.41M | 4.64M | 4.47M | 1.23M | 1.07M | 1.17M | 1.09M | 1.08M |
| OpEx % of Revenue | - | 83.7% | 96.27% | 97.11% | 120.82% | 139.09% | 231.28% | 102.92% | 101.05% | 91.77% | 85.28% | 101.19% | 150.13% | 145.17% | 161.5% | 145.05% |
| Selling, General & Admin | 154.52M | 144.01M | 175.68M | 128.15M | 125.33M | 122.08M | 84.01M | 11.31M | 8.41M | 4.64M | 4.47M | 1.21M | 1.07M | 1.17M | 1.09M | 1.08M |
| SG&A % of Revenue | - | 74.21% | 82.69% | 84% | 105.29% | 131.44% | 225.27% | 90.75% | 101.05% | 91.77% | 85.28% | 99.22% | 150.13% | 145.17% | 161.5% | 145.05% |
| Research & Development | 1.94M | 7.35M | 9.51M | 6.06M | 2.97M | 948.16K | 446.75K | 222.88K | 120.54K | 0 | 0 | 23.93K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 3.79% | 4.48% | 3.97% | 2.5% | 1.02% | 1.2% | 1.79% | 1.45% | - | - | 1.96% | - | - | - | - |
| Other Operating Expenses | 4M | 11.07M | 19.34M | 13.93M | 15.51M | 6.16M | 1.79M | 1.3M | -516.98K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -21.62M | -7.67M | -16.14M | -14.49M | -43.45M | -54.3M | -57.82M | -2.89M | -2.06M | -1.07M | -1.17M | -262.22K | -530.88K | -546.41K | -540.02K | -576.37K |
| Operating Margin % | -11.44% | -3.95% | -7.6% | -9.5% | -36.5% | -58.47% | -155.04% | -23.18% | -24.7% | -21.12% | -22.42% | -21.51% | -74.34% | -67.59% | -80.15% | -77.49% |
| Operating Income Growth % | - | 52.49% | -11.43% | 66.65% | 19.99% | 6.09% | -1900.94% | -40.54% | -92.61% | 9.12% | -347.98% | 50.61% | 2.84% | -1.18% | 6.31% | - |
| EBITDA | -13.58M | -361.24K | -6.65M | -7.89M | -39.68M | -53.43M | -57.42M | -2.55M | -1.86M | -975.98K | -1.14M | -218.47K | -473.9K | -489.43K | -483.05K | -519.68K |
| EBITDA Margin % | -7.19% | -0.19% | -3.13% | -5.17% | -33.33% | -57.53% | -153.97% | -20.48% | -22.35% | -19.31% | -21.78% | -17.92% | -66.36% | -60.55% | -71.69% | -69.87% |
| EBITDA Growth % | -227.29% | 94.57% | 15.67% | 80.12% | 25.74% | 6.95% | -2148.31% | -37.28% | -90.62% | 14.46% | -422.26% | 53.9% | 3.17% | -1.32% | 7.05% | - |
| D&A (Non-Cash Add-back) | 8.05M | 7.31M | 9.49M | 6.6M | 3.77M | 868.76K | 397.76K | 335.61K | 195.78K | 91.56K | 33.72K | 43.75K | 56.98K | 56.97K | 56.97K | 56.69K |
| EBIT | -21.5M | -8.83M | -16.14M | -14.81M | -39.69M | -58.3M | -57.82M | -2.89M | -2.06M | -1.28M | -1.17M | -134.96K | -473K | -282.08K | -459.48K | -498.87K |
| Net Interest Income | 123K | -1.36M | -2.18M | -2.6M | -1.28M | -3.02M | -1.67M | -761.15K | -354.39K | -100.52K | -48.61K | -37.48K | -4.68K | -3.38K | -3.37K | -21.26K |
| Interest Income | 126.22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.21K | 1.36M | 2.18M | 2.6M | 1.28M | 3.02M | 1.67M | 761.15K | 354.39K | 100.52K | 48.61K | 37.48K | 4.68K | 3.38K | 3.37K | 21.26K |
| Other Income/Expense | 123K | -2.52M | -2.18M | -2.92M | -1.21M | -7.02M | -2.58M | -761.15K | -354.39K | -150.91K | -48.61K | 89.78K | 53.19K | 260.95K | 77.18K | 56.24K |
| Pretax Income | -21.5M | -10.19M | -18.33M | -17.41M | -44.66M | -61.32M | -60.4M | -3.65M | -1.48M | -1.22M | -1.22M | -172.43K | -477.69K | -285.46K | -462.85K | -520.13K |
| Pretax Margin % | -11.38% | -5.25% | -8.63% | -11.41% | -37.52% | -66.02% | -161.96% | -29.28% | -17.84% | -24.11% | -23.35% | -14.15% | -66.89% | -35.31% | -68.69% | -69.93% |
| Income Tax | 13.9K | 45.72K | 402K | 428K | 360.7K | 7.7K | 122.5K | -122.5K | -124.7K | -12.49K | 0 | -13.2K | -17.2K | -17.2K | -17.2K | -17.2K |
| Effective Tax Rate % | -0.06% | -0.45% | -2.19% | -2.46% | -0.81% | -0.01% | -0.2% | 3.36% | 8.4% | 1.02% | 0% | 7.66% | 3.6% | 6.03% | 3.72% | 3.31% |
| Net Income | -21.92M | -7.11M | -18.88M | -20.6M | -45.54M | -60.9M | -58.65M | -3.14M | -1.24M | -1.21M | -1.11M | -61.99K | -460.49K | -268.26K | -445.65K | -502.93K |
| Net Margin % | -11.6% | -3.66% | -8.89% | -13.5% | -38.25% | -65.57% | -157.26% | -25.16% | -14.91% | -23.86% | -21.14% | -5.09% | -64.48% | -33.19% | -66.14% | -67.61% |
| Net Income Growth % | -376.33% | 62.36% | 8.32% | 54.77% | 25.23% | -3.84% | -1769.4% | -152.83% | -2.89% | -8.89% | -1686.59% | 86.54% | -71.65% | 39.8% | 11.39% | - |
| Net Income (Continuing) | -21.51M | -10.23M | -18.73M | -17.84M | -45.02M | -61.32M | -60.52M | -3.53M | -2.29M | -1.38M | -1.22M | -159.23K | -460.49K | -268.26K | -445.65K | -502.93K |
| Discontinued Operations | -409.26K | 3.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 1.44M | 2.06M | -475.55K | -1.03M | -2.18M | -141.06K | -77.96K | -259.08K | -6.55K | 80.91K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.46 | -0.23 | -0.53 | -0.70 | -1.57 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.07 | -0.04 | -0.08 | -0.07 |
| EPS Growth % | -204.7% | 56.6% | 24.29% | 55.41% | 30.84% | 46.46% | -1077.78% | -157.14% | 0% | 12.5% | - | 87.05% | -67.94% | 42.15% | -15.25% | - |
| EPS (Basic) | - | -0.23 | -0.53 | -0.70 | -1.57 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.08 | -0.05 | -0.08 | -0.07 |
| Diluted Shares Outstanding | 48.18M | 45.13M | 41.2M | 33.91M | 30.98M | 27.01M | 14.28M | 9.9M | 9.05M | 8.8M | 7.05M | 6.4M | 6.15M | 6.02M | 5.78M | 7.52M |
| Basic Shares Outstanding | 48.18M | 45.13M | 41.2M | 33.91M | 30.98M | 27.01M | 14.28M | 9.9M | 8.84M | 8.8M | 7.05M | 6.16M | 6.07M | 5.88M | 5.5M | 7.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying LFMD stock.
For fiscal year 2025, LifeMD, Inc. (LFMD) reported total revenue of $194.1M. This represents a 25988.7% increase compared to $0.7M in 2011.
LifeMD, Inc. (LFMD) reported a net loss of $7.1M for the fiscal year ending 2025.
LifeMD, Inc. (LFMD) reported an operating income of $-7.7M, resulting in an operating profit margin of -4.0%. This margin reflects the operational efficiency of the business before interest and taxes.
LifeMD, Inc. (LFMD) generated $154.8M in gross profit for the year, representing a gross profit margin of 79.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses despite revenue
Metrics are mathematically derived from official filings.
Revenue Growth Fading After 2025
Based on LifeMD's reported quarterly figures, revenue growth decelerated sharply from 48.8% year-over-year in 2025Q1 to a 24.0% decline in 2026Q2, with quarterly revenue falling from $65.7M to $47.3M over five quarters.
The reported figures suggest the growth phase that peaked in 2024 and early 2025 has reversed, with the year-over-year decline in 2026 pointing to weaker demand or a shift in the mix of revenue sources. The data does not disclose whether volume or pricing drove the contraction, so the durability of any recovery cannot be assessed from these figures alone. Investors should monitor whether the sequential decline stabilizes in subsequent quarters.
Gross Margin Expansion Masks Operating Losses
As reported in the financial statements, LifeMD's gross margin widened from 85.3% in 2024Q4 to 88.8% in 2026Q2, yet operating margin remained negative at -15.1% in the latest quarter.
The gross margin improvement suggests favorable product or channel economics at the unit level, but it does not translate into bottom-line profitability. The gap between gross margin and operating margin implies that the cost base sits largely in selling and administrative expense rather than in cost of goods. Investors should monitor whether gross margin expansion can eventually offset overhead without further revenue growth.
SG&A Absorbs Nearly All Gross Profit
Based on LifeMD's reported figures, SG&A of $41.7M in 2026Q2 consumed roughly 99% of the $42.0M gross profit, leaving an operating loss of $7.1M.
SG&A has remained elevated at roughly $35M to $46M per quarter across the ten-quarter window, even as revenue fell, which indicates limited operating leverage in the current cost structure. The reported figures suggest that overhead has not scaled down with the revenue decline, which may reflect fixed commitments or continued investment in customer acquisition. Without disclosure of the split between acquisition and administrative spending, the source of this rigidity cannot be determined from the data.
Persistent Losses Tempered by Small Profit Quarters
According to reported income statements, LifeMD posted net income in only two of ten quarters, with EPS swinging between -$0.20 and $0.01 and stock-based compensation between $2.1M and $4.2M per quarter.
The net income that appeared in 2025Q1 was driven by operating profit of $2.5M, but this was not sustained and reversed within the following two quarters. Stock-based compensation remains a recurring cost of several million dollars per quarter, which means reported losses are partly non-cash, though the figures do not indicate whether this offsets dilution concerns. The pattern suggests earnings quality is volatile and that single profitable quarters should not be extrapolated without confirmation of durable operating improvement.
Margin Strength Versus Shrinking Revenue Base
Based on LifeMD's reported figures, the bull case rests on an 88.8% gross margin, yet revenue has contracted for two straight quarters while operating losses of $7.1M in 2026Q2 persisted.
A bullish reading would emphasize the rising gross margin as evidence of pricing discipline or a richer product mix, but the reported figures suggest that gross profit dollars have fallen alongside revenue, weakening that argument. Short-side analysis would note that SG&A remains near $42M per quarter, so any further revenue decline mechanically deepens losses unless overhead is cut. The data does not show whether the revenue decline reflects temporary timing or structural demand loss, and that uncertainty warrants further investigation before any recovery thesis is accepted.